{
    "nct_id": "NCT06727773",
    "official_title": "Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer",
    "inclusion_criteria": "In order to participate in this study a subject must meet all of the eligibility criteria outlined below.\n\n* Written informed consent was obtained to participate in the study and HIPAA authorization for the release of personal health information. The subject is willing and able to comply with study procedures based on the judgment of the investigator.\n* Female\n* Age ≥ 50 years at the time of consent.\n* Stage I-III Breast Cancer\n* Completed at least 1 cycle of standard-of-care neoadjuvant or adjuvant chemotherapy\n* At least mild self-reported cognitive concerns ≥3 on a 0-10 scale\n* English-speaking\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 50 Years",
    "exclusion_criteria": "* Allergy to memantine\n* Previous radiation, cancer-directed hormonal therapy, chemotherapy (prior to the current regimen), or immune checkpoint inhibitors\n* Severe cognitive impairment, defined by Blessed Orientation Memory Concentration Test Score ≥11\n* >30 min vigorous or >60 min moderate physical activity per week\n* Myocardial infarction in the last 6 months\n* Cardiovascular or orthopedic limitations to exercise\n* Severe mental illness (i.e., schizophrenia or bipolar affective disorder) Current alcohol or drug abuse\n* Inability to swallow capsules </= 5mL/min\n* CrCl </= 5mL/min",
    "miscellaneous_criteria": ""
}